Close Menu

NEW YORK (360Dx) – Chembio Diagnostics said today that it has entered a collaboration with LumiraDx to develop point-of-care diagnostic tests for infectious diseases to address "significant global health threats."

Chembio said that it will receive funding from LumiraDx subject to satisfying certain milestones. If the tests receive regulatory approval and are commercialized in accordance with the agreement, Chembio will obtain royalty payments on resulting product sales and sell reagents to LumiraDx.

Additional terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

Sponsored by

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.